PTEN and endometrial cancer: As the combined effect of PARP and PI3K inhibitors is synergistic in PTEN mutated cells, and to a lesser degree, in PTEN wild-type cells, it may also provide a therapeutic option for endometrial cancers not solely dependent on their PTEN status.